Positron emission tomography (PET) biomarkers are stronger predictors of cognitive decline in Alzheimer’s disease (AD) than MRI measures of atrophy and demographic data.
Why this matters
This analysis simultaneously compared tau pathology, neuroinflammation and brain atrophy in patients with amyloid-positive mild cognitive impairment (MCI) and Alzheimer's dementia.
Increasing our understanding of how baseline measures of these three biomarkers predict cognitive decline across the whole spectrum of AD is critically important for two reasons. Firstly, it could provide a step forward in developing new prognostic markers of disease, and secondly, it could help develop effective tests that can ascertain the efficacy of new disease modifying therapies.